Trans-arterial Embolization for the Treatment of Facet Pain Due to Facet Arthropathy
NCT06965452
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
This single-site, single-arm study evaluates the feasibility, safety, tolerability, and efficacy of trans-arterial embolization (TAE) using Embozene microparticles for treating facetogenic pain due to facet arthropathy (osteoarthritis of the facet joints) in the lumbar spine.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Facet Joint Arthropathy
- Pain
- Osteoarthritis
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Not applicable
- Ages
- 18 to 85 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Northwell Health
- Last updated on ClinicalTrials.gov
- September 1, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
New York · 1
- North Shore University Hospital · Manhasset, NY
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.